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Abstract 
The detection of cytokines in body fluids, cells, tissues and organisms continues to 
attract considerable attention due to the importance of these key cell signalling 
molecules in biology and medicine. In this review, we describe recent advances in 
cytokine detection in the course of ongoing pursuit of new analytical approaches for 
these trace analytes with specific focus on immunosensing. We discuss recent elegant 
designs of sensing interface with improved performance with respect to sensitivity, 
selectivity, stability, simplicity, and the absence of sample matrix effects. Various 
immunosensing approaches based on multifunctional nanomaterials open novel 
opportunities for ultrasensitive detection of cytokines in body fluids in vitro and in 
vivo. Methodologies such as suspension arrays also known as bead assays together 
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with optical fibre-based sensors, on their own or in combination with microfluidic 
devices will continue to have an important role to address the grand challenge of 
real-time in vivo multiplex cytokine detection. 




Cytokines, low molecular weight (~ 6-70 kDa) soluble proteins secreted from the 
immune and non-immune cells are core indicators of the functional status of the body, 
and strongly associated with the immune system including the modulation of immune 
reactions such as sensitization.(Stenken and Poschenrieder 2015) Cytokines also play 
critical roles in chemically-induced tissue damage repair, in cancer development and 
progression, in the control of cell replication and apoptosis and in many other aspects 
of physiology. Consequently, monitoring cell functions and cell-to-cell 
communication by using their cytokine secretions has enormous value in biology and 
medicine.(O'Shea et al. 2011) The effects of cytokines are very potent as they engage 
various downstream amplification processes. As a result, only a few cytokine 
molecules may be sufficient to induce a significant cellular response.(Xue et al. 2015)  
 
Cytokines are classified into lymphokines (cytokines made by lymphocytes), 
monokines (cytokines made by monocytes), chemokines (cytokines with chemotactic 
activities), and interleukins (cytokines made by one leukocyte and acting on other 
leukocytes).(Nicola 1994) Based on effects of cytokines in the context of an 
inflammatory disease, they can also be divided into inflammatory or 
anti-inflammatory,(Wojdasiewicz et al. 2014) and produced both with and without 
stimuli such as lipopolysaccharide.(Zhao et al. 2011) Cytokines may act on the cells 
that secrete them (autocrine action), on nearby cells (paracrine action), or in some 
instances on distant cells (endocrine action). Cytokines can also act addictively, 




Cytokine detection and measurement is important as elevated concentrations of 
cytokines may indicate the activation of cytokine signaling pathways associated with 
inflammation or disease progression. Consequently, these proteins are widely used as 
biomarkers to characterize the immune function, understand and predict disease, and 
monitor effects of treatment.(Catalfamo et al. 2012)  Measurement sensitivity is 
always an issue for cytokines because they are released into the extracellular milieu 
resulting in pM concentration range.(Schenk et al. 2001) In addition to low 
concentrations, it is difficult to measure physiological concentrations of cytokines 
accurately and reproducibly due to some challenges (Figure 1) such as significant 
interference from heterophilic antibodies,(Bolstad et al. 2013) the rheumatoid 
factors,(Bartels et al. 2011) and specific or non-specific cytokine binding 
proteins,(Whicher and Evans 1990) and an extremely dynamic, transient cytokine 
secretion process.(Kulbe et al. 2012) 
 
 
Figure 1 The scheme showing challenges, requirements and strategies for cytokine 
detection. The challenges include complicated cytokine network, large number of 
different cytokines, low concentration of cytokines, and rapid dynamics of cytokine 
expression. Correspondingly, cytokine detection methods requires multiplex 
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capability, enhancement in selectivity and sensitivity, and real time measurement. The 
strategies to address these challenges are proposed to be application of sensor arrays, 
monoclonal antibodies, nanomaterials, multifluidic system, and et al. 
 
The most common approach for cytokine quantification is based on the idea of an 
immunoassay. Specific techniques include traditional ELISA assays,(Chiswick et al. 
2012) enzyme-linked immunosorbent spot (ELIspot) assays,(Cox et al. 2006) 
antibody array assays(Schröder et al. 2010) and bead-based assays(Won et al. 2012). 
Traditional ELISA assays are reliable, but they are not rapid (6 h) and usually require 
a relatively large sample volume (100 µL). Generally speaking, all these assays 
require a long sample preparation time (> 6 h), and multiplexed approaches require a 
high level of complexity in the sample labeling. Some assay types require specialized 
flow cytometry infrastructure, and all are unable to monitor the cytokines in real time 
or in a dynamic manner. These limitations are the driving force for researchers to 
develop sensitive, selective, and rapid real time cytokine analysis platforms for 
comprehensive characterization and quantitative analysis of cytokines released in both 
healthy and pathological conditions. 
The purpose of this review is to discuss recent advances in development of analytical 
approaches especially immunosensors for cytokine detection focusing on designing 
sensing interfaces to achieve high sensitivity, selectivity, stability, simplicity, and no 
sample matrix effects. This work is not intended to be a comprehensive review on 
cytokine detection, as several excellent reviews of analytical methods for 
measurement of cytokine proteins have been recently published.(Chikkaveeraiah et al. 
2012; Rusling et al. 2010; Stenken and Poschenrieder 2015) Rather, we will examine 
the latest trends in cytokine detection based on immunosensing.  
 
2. Principles of immunosensors 
Immunosensors are immunoreaction-based affinity biosensors, which use 
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immuno-compounds as biological receptors. They usually integrate an immunoassay 
and a directly associated transducer in a single device (Figure 2). This device contains 
two essential components: biorecognition domain and signal transduction. The 
biorecognition domain should be a biological entity such as antibodies, peptides, 
proteins, or even whole cells. The integration of recognition elements (such as 
antibodies and antigens) with a signal transduction usually achieved by modifying the 
transducer surface with a chemical layer that enables sensitive and selective 
immobilization of recognition species.(Liu et al. 2012a) Thus, ideally, this 
biorecoginition domain should have high affinity (low detection limit), high 
specificity and selectivity (low interference), wide dynamic range, fast response time, 
long shelf life, and good generality for detecting a broad range of analytes with the 
same class of surface fabrication. Signal transduction elements are responsible for 
converting molecular recognition events into physically detectable signals such as 





Figure 2 The general scheme of an immunosensor which includes matrix sample, 
biorecognition domain and signal transduction. Four important signal transduction 
approaches are schemed for cytokine detection, such as fluorescence 
immunosensirng, electrochemical immunosensing, surface plasmon resonance (SPR) 
based and microring resonator based immunosensing. 
The interaction of an antibody (Ab) with an antigen (Ag) forms the basis of 
immunosensors, which defines both specificity and detection limit of an 
immunosensor.(Mehrvar et al. 2000) The Ab-Ag interaction is characterized with an 




The ultimate detection limit of an immunoassay is determined by the antibody-antigen 
binding constant.(Moal and Bates 2012) The greater the binding constant of the 
antibody, the lower detection limit can be achieved. The affinity constant KA, which 
varies in strength from 104 to 1015 M-1 (typically of the order of 108 to 1012 M-1) 
depending on the nature of antigens and binding affinity of the corresponding 












Where [Ab], [Ag] and [Ab-Ag] are molar concentrations of antibody, antigen and 
antibody-antigen complex in solution, respectively. The transduction of such antibody 
and antigen biorecognition events either requires labels, commonly used in a myriad 
of immunoassay formats, or a method which can directly detect the change that occurs 
at the sensing interface. Most immunosensor devices reported to date perform indirect 
measurements by using labels such as enzymes,(Malhotra et al. 2012) fluorescent 
(Zhao et al. 2011) and chemiluminescent(Sardesai et al. 2013) probes that convert 
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affinity signal into a measurable response. Although indirect immunosensors are 
highly sensitive due to analytical characteristics of the label applied, the non-specific 
binding is a continuing problem.(Huang et al. 2015a) Therefore special methodologies 
to resist non-specific protein adsorption are critically required for sensing analytes in 
a complex matrix sample, such as blood or urine. Consequently, despite decades of 
effort it is still challenging to design a sensing interface with properties of high 
sensitivity, high selectivity, high stability, simplicity, and no matrix sample effect. 
The desire to have all of these properties simultaneously present at the same sensing 
interface drives research as well as commercial developments. 
3. Immunosensors for cytokine detection 
Given that cytokines are universal biomarkers implicated in the functioning of 
immune and other physiological processes, it is not surprising that cytokine detection 
is one of the hottest topics in immunosensing. However, publications reporting 
immunosensors for cytokine detection are limited due to some analytical challenges 
with cytokine detection (Figure 1). Table S1 lists representative immunosensors for 
cytokine detection based on different signalling strategies such as fluorescence 
immunoassay (FI), surface plasmon resonance detection (SPR), electrochemical-based 
methods (EC), silicon photonic micro-ring resonators (MR) and other methods. This 
section aims to generally describe the advantages and limitations with respect to each 
signal detection strategy, and a more detailed discussion of each of these different 
signalling strategies is reported elsewhere.(Stenken and Poschenrieder 2015)  
3.1 Fluorescence based immunsensing 
The fluorescence immunoassay (FI) is a method which monitors Ab-Ag binding based 
on changes in fluorescence signal (Figure 2), and recent publications outlining the 
principle of FI are summarized.(Wu et al. 2011) It represents the most widely studied 
methodology for cytokine detection due to its high sensitivity. In addition, fluorescent 
methods are simple, diverse and non-destructive, and can be integrated into 
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microfluidic devices for cytokine monitoring in real time.(Zhao et al. 2011) The wide 
abundance of different fluorescent labels makes FI technology capable of multiplexing. 
However, photobleaching of fluorescent dye labels and spectral overlap of reporter 
dyes may limit the degree of multiplexing, while luminescent background of sample 
matrix can interfere with the measurement and/or interpretation of results.(Campos et 
al. 2011) The detection limit of fluorescence based immunosensing ranges from fg 
mL-1 to ng mL-1, so it is generally sufficient for many cytokines in physiological 
conditions.  
3.2 Surface plasmon resonance based immunsensing 
SPR is an important tool to monitor interactions between biomolecules.(Mayer and 
Hafner 2011) Changes of the refractive index after Ab-Ag biorecognition can be 
probed by exploiting special properties of electromagnetic waves at the metal surface 
(surface plasmons). Thus the interaction between analyte and a biospecific element on 
metal surface can be monitored by SPR biosensor without the use of extrinsic labels 
(Figure 2). SPR has wide applications on sensing and recent publications outlining the 
principle of SPR are summarized.(Guo 2012) SPR-based immunosensors for cytokine 
detection are attractive due to high sensitivity (~2 pg mL-1)(Jeong et al. 2013) and the 
absence of labels. However, a common challenge with SPR-based sensors is the issue 
of overcoming signals produced via non-specific binding events on the sensor.  
3.3 Electrochemical based immunsensing 
Electrochemical methods (EC) have been used for protein detection by immunoassays 
for quite some time.(Luo and Davis 2013) In this approach, the Ab-Ag 
bioreconginition is probed based on the electrochemical signal from redox probes 
labelled on detection antibody (Figure 2). The primary advantages of electrochemical 
methods are inexpensive equipment and high sensitivity particularly in amperometric 
based measurements. More recent applications of electrochemiluminescence have 
incorporated various nano-based or chip-based strategies with high sensitivity (10 fg 
mL-1).(Sardesai et al. 2011) From Table S1 we can see electrochemical assays achieve 
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comparable detection limit to FL but with shorter analysis time. The scope of using EC 
for multiplexing is limited due to limited availability of redox probes for reporting the 
electrochemical signal.  
3.4 Microring resonator based immunsensing and other approaches  
MR represent a promising sensing platform (Figure 2) for real-time, label-free and 
multiplex detection of biomolecules due to their resonantly-enhanced sensitivity 
toward surface binding events between a target and antibody-modified 
micro-rings.(Washburn and Bailey 2011) Recent publications outlining the principle of 
MR sensors are summarized.(Amiri et al. 2015) The light coupled into the resonator via 
a waveguide is confined within the micro-ring cavity due to total internal reflections 
and high-Q resonant modes (Q~12000) are formed. Positions of these modes depend on 
the effective index of the resonant structure and thus get shifted when there is Ab-Ag 
interaction on the surface. This shift can be determined with high precision using the 
method of optical detection.(Qu et al. 2011) This is critical for field-based analytics 
and point-of-care diagnosis. For example, a silicon photonic micro-ring resonator was 
adopted for simultaneous detection of cytokines IL-2, IL-4, IL-5, and TNF-α with 
high accuracy in serum-containing cell media within only 5 min. (Luchansky and 
Bailey 2011) This report demonstrated that MR based sensing platforms have huge 
potential for multiplexed cytokine monitoring in complex immunological studies 
(Kindt and Bailey 2013) This approach also opened the possibility of performing 
real-time cells secretion measurements on single cells. Other new sensing platforms, 
such as, microarrays interferometric reflectance imaging sensors (IRIS)(Ahn et al. 2013) 
and arrayed imaging reflectometry (AIR)(Carter et al. 2011) are recently developed for 
cytokine detection with acceptable sensitivity (less than 10 pg mL-1).  
 
All these reported approaches aim to address one or more of detection challenges 
associated with cytokine detection: sensitivity (~10 pg mL-1 or better), selectivity, 
multiplexing, and real-time detection. Achieving high stability, simplicity, shorter 
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detection time and reduced sample volume are also driving the development of new 
cytokine immunosensing methods. The following sections are going to summarize 
strategies reported in literatures to meet the challenges of cytokine analysis including 
sensitivity, selectivity improvement, multiplex measurement, and real-time sensing. 
4. Strategies for improving selectivity 
4.1 Using monoclonal antibodies as the recognition reagent 
Immunoassays are attractive for the detection of proteins due to their high specificity 
by introducing monoclonal antibodies. Two types of antibodies (capture antibody and 
detection antibody) are normally used in sandwich immunosensors (Figure 2). It is 
preferable to use monoclonal antibodies as capture antibodies since they provide high 
selectivity to analyte.(Zhang et al. 2012a) Although not all cytokines have 
commercially available monoclonal antibodies, monoclonal antibodies are used 
whenever possible, with the majority of immunosensors for cytokine detection. To 
transduce such biorecognition events either requires labels or a transduction method 
(such as SPR or MR) which can detect the change that occurs at the sensing interface. 
Thus detection antibodies are normally labeled with probes such as fluorescent 
molecules or particles, redox probes,(Bettazzi et al. 2013) or mass tags.(Ahn et al. 
2013)  
4.2 Using aptamers as recognition reagents 
Aptamers are single strands of either DNA or RNA oligonucleotides that can be used 
to bind different analytes with higher selectivity and affinity than antibodies, and they 
are typically produced by selection from large combinatorial libraries.(Yüce et al. 
2015) Using aptamers as recognition reagents in biosensors has been reviewed in 
references.(Deng et al. 2014; Iliuk et al. 2011; Kim et al. 2016) The current active 
research on aptamers as alternative molecular recognition agents and possible 
substitutes for antibodies, has further widened the application of immunosensing in 
chemical analysis.(Famulok and Mayer 2011) In particular, aptamers can be readily 
site-specifically modified during chemical or enzymatic synthesis to incorporate 
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particular reporters, linkers, or other moieties. Also, aptamer secondary structures can 
be engineered to undergo analyte-dependent conformational changes, which opens up 
a wealth of possible signal transduction schemes, irrespective of whether the detection 
modality is optical, electrochemical, or mass based. Another advantage of using 
aptamers for specific target capture is their higher stability compared to antibodies. 
Consequently they can be used in harsh protein denaturing conditions.(Famulok and 
Mayer 2011) The vast majority of aptamer applications include simply using an 
aptamer as a substitute for an antibody. Despite active interest in these potential 
antibody substitutes, the number of aptamers that bind different cytokines is 
limited.(Orava et al. 2012) To our knowledge, in the field of cytokine detection only 
aptamers against IFN-γ, PDGF, VEGF, IL-6, IL-32, IL-17, and TNF-α have been 
reported in literatures. Revzin’s group has published several papers focusing on IFN-γ 
detection based on aptamer immunosensors.(Liu et al. 2012c; Liu et al. 2015; Liu et al. 
2011; Tuleuova et al. 2010) The sensitive and specific aptamer immunosensors for 
PDGF detection have been developed by combining aptamers with 
nanomaterials.(Wang et al. 2015; Wang et al. 2012a; Zhang et al. 2015) In one of 
such reports the hairpin aptamer probes have been immobilized on a gold electrode 
through self-assembly.(Zhang et al. 2012b) In this design, the presence of IFN-γ opens 
the hairpin structure. With subsequent addition of hemin, the hemin/G-quadruplex 
peroxidase-mimicking DNAzyme is formed, which catalyzes the electro-reduction of 
H2O2 and amplifies the current response for IFN-γ detection at the sub-nanomolar 
level. This aptasensor shows high selectivity towards the target analyte by 
incorporating a specific DNAzyme sequence into the hairpin aptamer probe. Hence, 
aptamers are becoming widespread in analytical applications not only as alternatives 
to antibodies, but as unique reagents in their own right. More examples on hairpin 
aptamer probes for both selectivity and sensitivity improvement will be discussed in 
section 5.4. 
4.3 Prevention of non-specific protein binding  
Modification of sensing interfaces with molecules being able to resist non-specific 
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adsorption is another efficient way to improve sensitivity and selectivity of the 
immunosensing system.(Zhang et al. 2013) Nonspecific adsorption of proteins is 
generally minimized by masking surfaces with blocking agents such as bovine serum 
albumin (BSA). However, for a complex biological sample such as serum, which 
contains numerous proteins of different types, BSA blocking solution might not be 
sufficient. Recently zwitterionic polymers have demonstrated high resistance to 
non-specific protein adsorption in biological applications.(Schlenoff 2014) Gooding’s 
group reported that zwitterionic phenyl layers have the anti-biofouling properties.(Gui 
et al. 2013) A hydrophilic layer such as poly(ethylene glycol) molecules (PEG) has 
also been explored to manage non-specific binding.(Liu et al. 2014a) Revzin and 
coworkers have been using modified PEG layers to improve the performance of 
aptamer immunosensors for cytokine detection.(Liu et al. 2011) PEG hydrogel has 
also been used to modify glass slide to resist the non-specific protein adsorption.(Seo 
et al. 2011) The application of polymer brushes in biomedical fields for resisting 
non-specific protein adsorption has been reviewed.(Krishnamoorthy et al. 2014) 
Hucknall and coworkers have designed a simple antibody microarrays on nonfouling 
poly(oligo(ethylene glycol) methacrylate) polymer (POEGMA) brushes (Figure 3) 
with femtomolar sensitivity for cytokines in serum and blood.(Hucknall et al. 2009) 
The nonfouling polymer brushes can efficiently resist protein adsorption from 
solution, and eliminate background non-specific signals in microarrays and lead to 
detection limits as low as 100 fg mL-1 (5 fM) in serum and 15 fM in whole blood. It is 
critically important to introduce molecules to sensing interface which can resist 
non-specific protein adsorption as the low detection limit depends on it. However, the 
problem of resisting non-specific protein adsorption has not yet been fully resolved. 
The management of non-specific binding remains one of the core challenges in 
cytokine analysis, and exploring reliable approaches to control non-specific protein 




Figure 3 Synthesis of POEGMA brushes on glass via surface-initiated atom-transfer 
radical polymerization for management of non-specific binding. Reprinted with the 
permission.(Hucknall et al. 2009)  
5. Strategies for improving sensitivity 
Numerous strategies attempt to achieve sensitivity improvement through signal 
amplification, including nanomaterial-based approaches,(Lei and Ju 2012) 
DNA-labeling techniques,(Hocek and Fojta 2011) electrochemiluminescence,(Chen et 
al. 2012) and in situ hybridization methods.(Urbanek et al. 2015) Here we only focus 
on techniques for improving sensitivity of cytokine detection based on signal 
amplification taking place on sensing interfaces.  
5.1 Amplified transduction with nanomaterials 
Generally, immunoreagents (such as antibodies) are immobilized on a transducer 
while the analyte (antigen) is measured through a label conjugated with one of the 
immunoreagents.(Pei et al. 2013) Nanomaterial-based fluorescent, luminescent, 
refractive index, light scattering and/or colorimetric labels have been integrated into 
analytical chemistry and used by large number of novel sensing techniques.(Scida et 




advantages over traditional approaches in terms of sensitivity, stability, and capability 
for multiplexing and real time detection.(Chen and Chatterjee 2013) Importantly, 
nanomaterials can be functionalised to improve their ability to bind in a designated 
location, such as the surface of a cytokine secreting cell and signal the presence of 
proteins. They can be coated with antibodies, antigens, aptamers, enzymes specific to 
a protein, or receptors overexpressed on cell surface, or specific to cancer biomarkers. 
These nanomaterials can accommodate a large number of such targeting moieties due 
to high area-to-volume ratio, which makes nanomaterials attractive in biosensors.  
 
For example, zinc oxide nanorod platform was reported for ultrasensitive fluorescence 
detection of IL-18 and TNF-α with the sensitivity of sub fg mL-1.(Adalsteinsson et al. 
2008) A gold nanoparticle (AuNP) based SPR immunosensor combined with a fluidic 
platform was developed for detection of TNF-α.(Oh et al. 2014) This cytokine 
secretion assay was sensitive enough to quantify intercellular-signaling proteins 
secreted by blood immune cells in 4-5 h which is 3 times shorter than in the 
traditional ELISA method. Surface Enhanced Raman Spectroscopy (SERS) based 
AuNP sensing platform has been developed for fast, wash-free, and multiplexed 
quantification of three cytokines, INF-γ, IL-2, and TNF-α, with the detection limit of 
0.5 pM, 1.5 pM, and 0.3 pM, respectively.(Wang et al. 2013) By combination of the 
advantages of AuNP loaded graphene nanosheets, quantum dot based amplification, 
and heated electrode measurement, Zhang et al have proposed an ultrasensitive for the 
detection of IL-6 with detection limit of 0.5 pg mL-1.(Zhang et al. 2011) In addition, 
AuNPs uniformly assembled on the surface of poly (styrene-acrylic acid) nanospheres 
have been also reported as a tool for detection of TNF-α with high sensitivity (0.01 ng 
mL-1), stability and reproducibility.(Yin et al. 2011) Aptamer conjugated gold 
nanorods were used in a dual role as a label and a substrate to conjugate antibodies for 
a multiplex serum cytokine immunoassay detected by localized SPR in a microfluidic 
system.(Chen et al. 2015) The key achievement in this study is simultaneous detection 
of multiple analytes (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ) with high sensitivity 
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(5-20 pg mL-1) from a 1 μL serum sample within 40 min.  
 
Huang and coworkers have developed single molecule nanoparticle optical biosensors 
(SMNOBS) based on silver nanoparticles (2.6 ± 1.1 nm),(Huang et al. 2008) which 
were used for sensing and imaging of single TNF-α molecule. Once a single TNF-α 
molecule bound to a single monoclonal antibody molecule on single nanoparticle, the 
localized SPR of SMNOBS exhibited a large red shift of peak wavelength. These 
authors reported a dynamic range of at least 0-200 ng mL-1 TNF-α. A graphene 
oxide-based amperometric sensor was reported for a highly-sensitive detection of IL-6 
with the detection limit of 4.7 pg mL-1.(Huang et al. 2013a) An 
electrochemiluminescent immunosensor based on carbon nanotubes has been 
developed for detection of IL-6 in serum with detection limit of 0.25 pg mL-1 (Figure 
4).(Sardesai et al. 2011) In this work carbon nanotubes were conjugated with the 
capture antibodies and the reporter silica nanoparticles with detection antibodies. An 
electrochemical immunosensor for measuring IL-6 in serum based on single wall 
nanotube forests and 5 nm glutathione-protected AuNPs were also developed.(Munge 
et al. 2009) Their analytical performance was approaching the physiological range for 
IL-6 (< 6 pg mL−1) with detection limit of 10 pg mL−1.   
 
 
Figure 4 Design of microfluidic ECL array. Reprinted with permission.(Sardesai et al. 
2011) 




nanoparticle labels was developed for TNF-α measurement. (Yuan et al. 2011) Both 
electrochemical and electrochemiluminescence measurements can be used to quantify 
TNF-α with detection limit of 3 pg mL-1 and 7 pg mL-1, respectively. The increased 
sensitivity of TNF-α was achieved by an increase of CdTe QD loading per 
immunoassay event due to a large number of surface functional epoxy groups on 
polymers. In addition to increase the loading number of capture antibodies, the 
application of specially designed nanomaterials on the electrochemical sensing 
interface can greatly increase electron transfer rate between biomolecules and 
transducer resulting in increased sensitivity.(Liu et al. 2014b) An ultrasensitive 
electrochemical microfluidic array optimized to measure a four-protein panel of 
cytokines (IL-6, IL-8, VEGF and VEGF-C) with detection limits in the 5-50 fg mL-1 
range was developed by Rusling’s group.(Malhotra et al. 2012) The sensitivity was 
improved by using off-line protein capture by magnetic beads carrying 400,000 
horseradish-peroxidase enzyme labels and ∼100,000 antibodies. For enhancing the 
sensitivity, a strategy for detection of IL-2 which relies on silicon photonic microring 
resonator was reported by Bailey and coworkers.(Luchansky and Bailey 2011) In this 
study the signal arising from the initial binding event was amplified by employing a 
much larger secondary antibody due to significant change in mass, hence refractive 
index affecting resonance conditions.  
 
These examples above show enormous scope of nanomaterials offering for 
immunosensing of cytokines in regards to signal amplification. There is a similar 
scope to covalently attach multifunctional components (biomolecules and anti-fouling 
molecules) onto nanomaterials without steric hindrance and exploitation of these ideas 
for cytokine detection is likely to lead to further advances in sensitivity. 
5.2 Microsphere‐based amplified transduction 
In addition to nanomaterials, functionalized magnetic particles have been commonly 
used for purposes such as manipulation of cells, (Xu et al. 2011) isolation of specific 
DNA molecules,(Fitzgerald and Grivel 2013) or detection of biomarkers.(Joo et al. 
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2012) The large surface of a microsphere makes it possible to increase the sensitivity 
because a large number of antibodies can be attached. Simultaneous detection of six 
cytokines IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α in equine plasma using fluorescent 
microsphere immunoassays (FMIA) has been reported.(Hall et al. 2015) Compared 
with ELISA, FMIA has a higher sensitivity (~41 pg mL-1). An electrochemical 
bioassay for analysis of TNF-α as low as 44 pg mL-1 was developed by coupling 
magnetic beads with disposable electrochemical platforms.(Bettazzi et al. 2013)  
5.3 Surface-based signal enhancement tools 
Recently, surface enhancement approaches have been developed to increase 
fluorescence signals from the available number of fluorophore labels to improve the 
sensitivity of fluorescence based assays. This approach uses either photonic crystals 
(PC) or, more commonly, metal nanostructures to enhance the sensitivity of molecular 
detection. SERS based surfaces have also been intensely investigated and show 
particular promise for sensitive cytokine detection.(Cialla et al. 2012) PC surfaces can 
enhance sensitivity of cytokine through the use of narrow bandwidth optical 
resonances that are designed to occur at specific combinations of excitation 
wavelength and incident angle. An ultrasensitive immunoassay based on 
nanoparticles-assembled PC was developed for detection of human epidermal growth 
factor receptor 2 (HER, breast cancer biomarker) with a detection limit as low as 10 
aM in less than 10 μL of serum-based sample.(Han et al. 2012) A PC surface was 
designed for multiplex cytokine detection which can improve the detection limit by a 
factor of seven.(Huang et al. 2011) Recently, embedding PC surface in the 
microfluidic chip resulted in 20 times fluorescence enhancement, which was applied 
for detection of TNF-α and IL-3 with 80 fM detection limits. (Tan et al. 2015) A 
fluorescence-enhancing microarrays on plasmonic gold films for multiplexed cytokine 
detection with up to three orders of magnitude higher sensitivity than on conventional 
nitrocellulose and glass substrates were developed.(Zhang et al. 2013) The approach 
was used for detection of VEGF, IL-1β, IL-4, IL-6, IFN-γ and TNF-α in a panel through 
a four-layer immunoassay approach. This work demonstrated a high throughput 
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multiplexed cytokine detection method with one order higher sensitivity (0.06 pg 
mL-1) and two order higher dynamic range than the conventional ELISA.  
 
Fiber-optic sensors are chemically passive, have small physical dimensions, and are 
able to access challenging environments.(Wang and Wolfbeis 2012) They offer an 
advantage of long interaction length which, in some situations can yield enhanced 
signals. Moreover, optical fiber biosensors can be used in combination with different 
types of spectroscopic techniques, e.g. absorption, fluorescence, phosphorescence, 
Raman, SPR. It is therefore not surprising that optical fibers were explored as an 
interesting platform for cytokine detection.(Huang et al. 2013b; Jeong et al. 2013) 
One of the published approaches was based on fiber-optic SPR for detection of IL-1, 
IL-6, and TNF-α in a buffered saline solution and a spiked cell culture 
medium.(Battaglia et al. 2005) In this study, the detection limit of IL-6 was reached to 
be 0.44 ng mL-1. It has also been demonstrated that optical fiber based sensors has 
potential for real-time monitoring of biologically relevant molecules in complex 
biological fluids. A fiber-optic localized surface plasmon resonance sensor was 
fabricated for detection of IFN-γ using spherical AuNPs on a flattened end-face of 
optical fiber.(Jeong et al. 2013) The authors emphasized that the fabricated SPR 
sensor can be used for real-time label-free immunoassay, by the virtue of having a fast 
detection time (5 min), high resolution and sensitivity (2 pg mL-1 for IFN-γ).   
5.4 Hairpin DNA probes based amplification strategy 
Recently lots of research work on hairpin DNA probe based immunosensors for the 
ultrasensitive detection of biomarkers has been reported.(Ge et al. 2016; Gong et al. 
2014; Guo et al. 2015; Yao et al. 2014; Zhang et al. 2014a; Zhang et al. 2014b) This 
topic has been symmetrically reviewed.(Huang et al. 2015b) As an example, a hairpin 
aptamer DNAzyme probe was used for sensitive and visual detection of IFN-γ based 
on an original quadratic amplification strategy (Figure 5).(Zhou et al. 2013) In this 
study, the addition of target IFN-γ resulted in two recycling amplification cycles with 
19 
 
assistance of Bst-polymerase and λ exonuclease to generate numerous 
G-quadruplex/hemin DNAzymes. Colorless ABTS2- is converted into to a green-color 
product ABTS- with presence of H2O2. This produces a dramatic color change of the 
solution which enables highly sensitive visual detection of IFN-γ (50 pM) with the 
naked eye. Using the similar amplification strategy as Zhou et al, Zhang and 
coworkers developed a method to quantify IFN-γ with two orders higher sensitivity 
(0.1 pM).(Zhang et al. 2014b) Recently, a new type of amplified fluorescence 
polarization (FP) aptasensor based on allostery-triggered cascade strand-displacement 
amplification (CSDA) and polystyrene nanoparticle (PSNP) enhancement for 
ultrasensitive detection of cytokines has been developed.(Huang et al. 2015c) The 
assay system consists of a fluorescent dye-labeled aptamer hairpin probe and a 
PSNP-modified DNA duplex (assistant DNA/trigger DNA duplex) probe with a 
single-stranded part and DNA polymerase. Two probes coexist stably in the absence 
of target, and the dye exhibits relatively low FP background. Upon recognition and 
binding with a target protein, the stem of the aptamer hairpin probe is opened, after 
which the opened hairpin probe hybridizes with the single-stranded part in the 
PSNP-modified DNA duplex probe and triggers the CSDA reaction through the 
polymerase-catalyzed recycling of both target protein and trigger DNA. Throughout 
this CSDA process, numerous massive dyes are assembled onto PSNPs, which results 
in a substantial FP increase that provides a readout signal for amplified sensing 
process. This newly proposed amplified FP aptasensor enables the quantitative 
measurement of VEGF165 with a detection limit of 86 aM, which is about six orders of 




Figure 5 The principle of novel quadratic amplification strategy for highly sensitive 
visual detection of IFN-γ. Reprinted with the permission.(Zhou et al. 2013)  
6. Multiplex cytokine detection 
Cytokines act in concert to function in network of effectors. In clinical studies, a 
multianalyte profiling approach provides more information on the cytokine network 
than a single-analyte measurement, as several cytokines need to be tested in each 
sample, ideally in real time. The quantitation of multiple analytes by multiplexed 
immunoassays offers the advantages of specificity and reduced sample and reagent 
volumes with implications for the cost-effectiveness of assay. The most popular 
methods for multiplex cytokine detection are based on color-coded beads and biochip 
assays. 
6.1 Colour-coded beads 
In high-throughput sensing technologies, the encoding microbeads and nanoprobes 
with a unique code is widely used to identify the attached ligand molecules. Blicharz 




the use of a fluorescence microscope for the analysis of inflammatory cytokines in 
saliva.(Blicharz et al. 2009) The multiplexed antibody array in the study achieved 
simultaneous detection of ten cytokines associated with pulmonary inflammatory 
diseases in saliva. Only 100 μL sample was used and the total assay time was 2.5 h. 
Another bead-based platform reported in the literature to exploited ECL for 
simultaneous detection of antigens VEGF, IL-8, and TIMP-1 by imaging fluorescently 
encoded microbeads individually located in a microwell array.(Deiss et al. 2009) The 
multiplexed ECL platform in this case was an electrode prepared from etched fiber 
optic bundles coated with gold (Figure 6). The ECL from the array was viewed with a 
microscope by performing a cyclic voltammogram. This work was the first 
demonstration that individual sensing bead can be imaged by ECL in a multiplexed 
sandwich immunoassay.  
 
Figure 6 The sandwich immunoassay procedure. The beads are loaded into 
microwells created in an etched gold-coated ﬁber-optic bundle which acts as the 





6.2 Sensor arrays 
Color coded beads (suspension arrays) are popular choice for multiplex cytokine 
detection, but there are limitations on the number of distinguishable codes in the same 
array. To overcome this obstacle, a new encoding approach was developed by the 
combination of QD and magnetic NPs with nanosphere structure which ensures a 
greatly enlarged encoding capacity by tuning the magnetic field.(Song et al. 2014) 
This approach has applied to detection of IgG to demonstrate the reliability of NPs as 
encoded carriers in multiplex immunoassays.(Stoeva et al. 2006) The result is that 
NPs conjugated with specific antibodies have bound only to the corresponding 
positive antigen immobilized on the substrate. In addition, the reproducibly obtained 
detection limit of IgG was low as 1 fM. The very bright and spectrally narrow NPs 
Raman tags using SERS provide new opportunities for the optical encoding 
systems,(Wang et al. 2012b) and are expected to revolutionize high-throughput 
bioanalysis where multiplexing at high levels is needed. With tunable optical 
waveguides, silicon photonic MR has been demonstrated great potential for multiplex 
cytokine detection.(Sloan et al. 2013) In addition, using the multiplicative effects of 
optical resonant coupling to the PC in increasing the electric field intensity 
experienced by fluorescent labels and the spatially biased funneling of fluorophore 
emissions through coupling to PC resonances, PC enhanced fluorescence can be 
adapted to increase the sensitivity (pg mL-1 level) towards multiplex cytokine 
detection.(George et al. 2013) 
7. Real time cytokine detection 
7.1 Microfluidic system 
Dynamic changes in analyte concentration are difficult to be measured in real time 
and in many cases this can only be done with special microfluidic devices.(Singhal et 
al. 2010) Microfluidic devices process volumes of fluids on the order of nanoliters 
and are capable to achieve multiplexing, automation, and high-throughput screening. 
The coupling and integration of a sensing system in a microfluidic device has 
23 
 
successfully been applied for real-time analysis with a small amount of 
sample.(Konry et al. 2013) Quasi-real time cytokine detection has been realized by 
combining immunoassays with a micro fluidic device.(Nie et al. 2014) For example, a 
simple lab-on-a-chip biosensor was developed to perform near real-time diagnostics 
of clinically relevant analytes such as cytokines and antibodies.(Cohen et al. 2015) In 
this work, the reagent volumes were reduced to 0.5 µL (nearly three orders of 
magnitude less than in a conventional assay), and the washing steps required in 
standard immunoassays were eliminated by the same chip. In addition, the detection 
process could be accomplished in seconds (nearly in real-time) in the flow through 
incubation channel.  
In another example demonstration of this approach, IFN-γ released from an individual 
T-cell was detected by immunsensors integrated into a microfluidic chip.(Zhu et al. 
2008) In this study, cell purification and cytokine detection were performed on the 
same microdevice which was able to significantly reduce the detection time to 1 h and 
sample blood volume 3 µL (Figure 7). The microfluidic chips are also compatible 
with multiplexing. For example a multi-analyte aptasensor for rapid detection of 
cytokines has been developed.(Liu et al. 2011) In this study, IFN-γ was labeled with 
anthraquinonoid (AQ), and TNF-α was labeled with methylene blue (MB) redox 
reporters respectively. Once the cytokine conjugated with the corresponding aptamer, 
the now modified conformation of the aptamer resulted in decreased redox current. 
These microfluidic devices were integrated with the aptasensor by standard soft 
lithography. The cytokines released from T-cells or monocytes were monitored on the 




Figure 7 (A) The conceptual design of microarrays for detection of T-cell-secreted 
cytokines. (B) A map of the 8 × 20 microarray for capturing T-cells and detecting 
T-cell-secreted IL-2 and IFN-γ. (C) Design of a microfluidic platform employed for 
integration with Ab microarrays. (D) An image of a PDMS microdevice employed for 
T-cell capture and cytokine detection experiments with one reaction chamber filled 
with unlysed whole blood. Reprinted with permission.(Zhu et al. 2008)  
 
Another multiplex method based on EC was developed using a silicon chip 
technology for real time detection of IL-1, IL-10, and IL-6 which were secreted in 
acute stages of inflammation after implantation of a surgical device into the 
patient.(Baraket et al. 2014) The fabricated silicon chip incorporated an array of eight 
gold microelectrodes which allow simultaneous detection of different cytokines 
through electrically addressable diazonium-functionalized antibodies. The interactions 
between cytokines and corresponding antibodies were monitored by electrochemical 
impedance spectroscopy. This design was highly sensitive towards three cytokines in 




aptasensing surface combined with microfluidics was employed by other authors for 
detection of IFN-α and TNF-γ which were released from immune cells.(Liu et al. 
2012c) In the study, anti-IFN-α DNA aptamers and anti-TNF-γ RNA aptamer were 
thiolated and fuctionalized with the methylene blue redox reporter (Figure 8). The 
microdevice consisted of two parallel microfluidic channels, each channel containing 
four cell capture/sensing sites. Upon mitogenic activation, the secreted IFN-γ and 
TNF-α molecules were captured by aptamers, and monitored by performing square 
wave voltammetry at different time points at individually addressable electrodes. The 
detection limit of IFN-α and TNF-γ was found to be 0.06 nM and 0.58 nM, 
respectively.  
 
Figure 8 (A) Schematic of a pair of half ring-shaped Au electrodes were modified 
with different cytokine-binding aptamers. (B) Electrode layout. (C) 300 µm diameter 
of PEG wells are used to capture approximately 400 cells inside one well. Reprinted 
with the permission.(Liu et al. 2012c) 
 
Microfluidics, aptasensors, and surface micropatterning were also combined to detect 
local IFN-γ released from the captured CD4 T cells from a heterogeneous cell sample 
in real time.(Liu et al. 2011) The sensing mechanism is based on a change in hairpin 
conformation due to binding of cell-secreted cytokine molecules. To this aim, sensing 
electrodes were packaged in PEG so as to define cell attachment sites in the proximity 
of each electrode. These attachment sites were modified with anti-CD4 Ab to promote 
binding of CD4 positive T-cells. Upon infusing the sample (red blood cell lysed blood) 
into fluidic channels, leukocytes were captured next to sensing electrodes and 
stimulated to produce cytokines. The IFN-γ released by cells was then detected at the 




makes it possible to detect local concentration of IFN-γ released from live cells in real 
time, and the signal appear as early as 15 min after when as few as 90 T-cells are 
stimulated.  
 
Bhavsar and co-workers developed a gold electrode electrochemical impedance 
immunosensor for label-free and sensitive detection of IL-12 in physiological fluids 
with the detection time of 90 s.(Bhavsar et al. 2009) An amperometric sensor was 
reported by Huang and coworkers for detection of IL-6 with the sensitivity of 4.7 pg 
mL-1.(Huang et al. 2013a) This research provides a promising starting point for future 
development of highly-sensitive, real-time cytokine detection.  
7.2 Biochips 
Designing suitable biochips is another approach to achieve dynamic and local 
monitoring of cytokine expression. This is an active area of research and recent trends 
in protein biochip technology has been reviewed.(Reddy Jr et al. 2015) Several groups 
are employing antibody-modified surfaces in conjunction with detection technologies, 
such as SPR to monitor cytokine secreted from cells in real time.(Milgram et al. 2011; 
Valentina et al. 2015)  This is a promising direction for dynamic, label-free sensing, 
but the problem of expensive instrumentation will need to be addressed and detection 
of specific cell-secreted cytokines has yet to be demonstrated. In a few instances the 
biochip technology has been combined with the microfluidic system to realize the real 
time detection.(Jokerst et al. 2010) 
8. Practical considerations in cytokine immunosensing 
For designing an immunosensing device, stability is a crucial factor besides the 
sensitivity, selectivity, and other factors reviewed in above sections. Among various 
methods for binding, covalent coupling is one of the best functionalization approaches 
because it results in a strong and stable attachment of desired biomolecules on the 
substrate.(Liu et al. 2014b) The traditional self-assembled monolayer (SAM) of thiols 
are widely used in many studies, but this approach has many limitations.(Civit et al. 
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2010) Recently, aryldiazonium salt chemistry-based surface functionization has 
attracted many researchers because it can overcome the disadvantages of gold thiol 
chemistry while keeping its advantages. In addition, aryldiazonium salts with different 
terminal groups can be grafted on various materials to form stable covalent bonds, 
which significantly widens its application in sensing.(Mahouche-Chergui et al. 2011)  
Our team has reported many immunosensing interfaces based on the stable 
aryldiazonium salt chemistry.(Liu et al. 2014a; Liu et al. 2012b; Liu et al. 2014b) 
Recently Arya et al. presented a new platform based on 4-fluoro-3-nitrophenyl grafted 
gold disk electrode for label free quantification of IL-2 with detection limit of 1 pg 
mL-1.(Arya and Park 2014) Besides formation of stable organic layers on interface, 
the stability of antibody on sensing interface is another important factor that can 
significantly affect sensor performance.(Ahn et al. 2013) The desorption of antibodies 
reduces the surface density of capturing molecules which leads to false 
negatives.(Ahn et al. 2012) Although, stability is essential for the sensing device 
development, it is surprising to find that the stability of sensing interface is 
infrequently discussed in the context of cytokine detection. Hence, there is plenty of 
scope for improvement in this area. 
 
Reproducibility is another important property of a successful biosensor. Only a few 
studies focus on this topic for cytokine detection.(Agalliu et al. 2013; Hosnijeh et al. 
2010) To our knowledge, the reported methods for cytokine immunosensing mostly 
concentrate on the increase in sensitivity and decreased sample volume but not on 
reproducibility, which might be due to the challenges of cytokine detection as we 
summarized in Figure 1. Thus this review will not be able to satisfactorily cover this 
topic. 
9. Commercial cytokine detection assays 
A number of commercial cytokine kits based on different platforms are available and 
listed at Table S2. Despite these active activities on cytokine kit development, the 
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precision and reproducibility of these new approaches have not been well defined. In 
a study of multianalyte bead-based (Luminex) kits, the World Health Organization 
(WHO) cytokine standards were assayed at the same expected concentrations as the 
standards provided with each kit, but the WHO and kit standards often yielded very 
different absolute concentrations.(Nechansky et al. 2008) For example, the IL-4 
standard from Linco was greatly (more than 1 log) underestimated in the Linco kit 
compared to the WHO standards although the read-out obtained with the IL-2 
standards provided by all kits were in accordance with the WHO standard. In addition, 
multiple studies have compared standard-sensitivity multiplex assays with each 
other.(Breen et al. 2011; Moncunill et al. 2013; Richens et al. 2010) These comparison 
studies have shown variable agreement among assays and have indicated that absolute 
cytokine concentrations differ across testing platforms. Such variability is not unique 
to multiplex assays, as proficiency testing has demonstrated that absolute 
concentrations of cytokines measured by a single-analyte ELISA can vary widely 
from lab to lab, although a similar rank order of cytokine concentrations between 
samples is often preserved. Differences in the number of samples detected in accurate 
range and reproducibility were observed depending on the method used and even the 
cytokine detected, although Luminex-based kits were found to be highly reproducible 
and reliable.(Berthoud et al. 2011) Hence, the cytokine amount measured was 
critically influenced by the actual kit used. The quantitive determination of cytokines 
and therefore their use as biomarkers in serum samples have to be interpreted with 
specified conditions. 
10. Conclusion and future perspectives 
Cytokine immunosening approaches provide powerful tools for future of infectious 
disease diagnosis and drug screening.(Zhou et al. 2012) Hence, there is continuing 
demand for cytokine detection by immunosensing. The significant cytokine detection 
challenges can be met by designing functional sensing interfaces with improved 
performance. For example, engineering nanomaterials applied to the sensing interface 
or using surface enhancement techniques can greatly increase detection sensitivity. 
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Introducing monoclonal antibodies, aptamers, or anti-biofouling molecules to the 
sensing interface provides a pathway to improve selectivity. In addition, conjugation 
detection antibodies with different labels helps realize multiplex cytokine detection. 
More importantly, it is possible to achieve real time cytokine detection by integrating 
microfluidic devices, new nanotechnology tools and different transducer methods. 
Selected exciting technologies for cytokine analysis proposed and developed by 
various groups, have been outlined in this review.   
 
What about the future for cytokine detection? Regardless of multiple recent 
developments, ELISA is likely to remain the standard workhorse for cytokine 
detection. The ability to measure multiple cytokines simultaneously and in real time is 
extremely important in a variety of physiological conditions, because the concentration 
fluctuation of one cytokine often induce changes in other networked cytokines. Thus 
more efforts need to be invested in finding improved labels which are able to report the 
optical or electrochemical signals efficiently. Together with fibre-optical based sensors, 
colour-coded beads combining with microfluidic devices will have great potential for 
real time in vivo multiplex cytokine detection in the future.(Revzin et al. 2012) 
Moreover, aptamer based biosensors will be the next hot topic for cytokine detection 
because of their high stability, while aptamers against more cytokines will be required. 
Therefore, research in the area of cytokine immunosensing is in its early stages, and 
will continue to grow. Its further development will have significant effect on cytokine 
biology and early diagnosis of a range of diseases. 
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Pei, X., Zhang, B., Tang, J., Liu, B., Lai, W., Tang, D., 2013. Anal. Chim. Acta 758, 1-18. 
Qu, W., Liu, Y., Liu, D., Wang, Z., Jiang, X., 2011. Angew. Chem. Int. Ed. 123(15), 3504-3507. 
Reddy Jr, B., Salm, E., Bashir, R., 2015. Annu. Rev. Biomed. Eng. 17(1). 
Revzin, A., Maverakis, E., Chang, H.-C., 2012. Biomicrofluidics 6(2), 021301. 
Richens, J.L., Urbanowicz, R.A., Metcalf, R., Corne, J., O’Shea, P., Fairclough, L., 2010. J. Biomol. 
Screen. 15(5), 562-568. 
Rusling, J.F., Kumar, C.V., Gutkind, J.S., Patel, V., 2010. Analyst 135(10), 2496-2511. 
Sardesai, N.P., Barron, J.C., Rusling, J.F., 2011. Anal. Chem. 83(17), 6698-6703. 
33 
 
Sardesai, N.P., Kadimisetty, K., Faria, R., Rusling, J.F., 2013. Anal. Bioanal. Chem. 405(11), 
3831-3838. 
Schenk, T., Irth, H., Marko-Varga, G., Edholm, L., Tjaden, U., van der Greef, J., 2001. J. Pharm. 
Biomed. Anal. 26(5), 975-985. 
Schlenoff, J.B., 2014. Langmuir 30(32), 9625-9636. 
Schröder, C., Jacob, A., Tonack, S., Radon, T.P., Sill, M., Zucknick, M., Rüffer, S., Costello, E., 
Neoptolemos, J.P., Crnogorac-Jurcevic, T., 2010. Mol. Cell. Proteomics 9(6), 1271-1280. 
Scida, K., Stege, P.W., Haby, G., Messina, G.A., García, C.D., 2011. Anal. Chim. Acta 691(1), 6-17. 
Seo, J.H., Chen, L.J., Verkhoturov, S.V., Schweikert, E.A., Revzin, A., 2011. Biomaterials 32(23), 
5478-5488. 
Shen, J., Li, Y., Gu, H., Xia, F., Zuo, X., 2014. Chem. Rev. 114(15), 7631-7677. 
Singhal, A., Haynes, C.A., Hansen, C.L., 2010. Anal. Chem. 82(20), 8671-8679. 
Sloan, C.D.K., Marty, M.T., Sligar, S.G., Bailey, R.C., 2013. Anal. Chem. 85(5), 2970-2976. 
Song, E., Han, W., Li, J., Jiang, Y., Cheng, D., Song, Y., Zhang, P., Tan, W., 2014. Anal. Chem. 86(19), 
9434-9442. 
Stenken, J.A., Poschenrieder, A.J., 2015. Anal. Chim. Acta 853, 95-115. 
Stoeva, S.I., Lee, J.S., Smith, J.E., Rosen, S.T., Mirkin, C.A., 2006. J. Am. Chem. Soc. 128(26), 
8378-8379. 
Tan, Y., Tang, T., Xu, H., Zhu, C., Cunningham, B.T., 2015. Biosens. Bioelectron. 73, 32-40. 
Tuleuova, N., Jones, C.N., Yan, J., Ramanculov, E., Yokobayashi, Y., Revzin, A., 2010. Anal. Chem. 
82(5), 1851-1857. 
Urbanek, M.O., Nawrocka, A.U., Krzyzosiak, W.J., 2015. Int. J. Mol. Sci. 16(6), 13259-13286. 
Valentina, M., Jan, F., Peder, N.L., Bo, Z., Hongjie, D., Pernille, K., 2015. BMC Biotech.15(1), 73. 
Wang, G., Zhu, Y., Chen, L., Zhang, X., 2015. Biosens. Bioelectron. 63, 552-557. 
Wang, X., Ishii, Y., Ruslinda, A.R., Hasegawa, M., Kawarada, H., 2012a. ACS App. Mat. Interfaces 
4(7), 3526-3534. 
Wang, X.D., Wolfbeis, O.S., 2012. Anal. Chem. 85(2), 487-508. 
Wang, Y., Tang, L.J., Jiang, J.H., 2013. Anal. Chem. 85(19), 9213-9220. 
Wang, Z., Zong, S., Li, W., Wang, C., Xu, S., Chen, H., Cui, Y., 2012b. J. Am. Chem. Soc. 134(6), 
2993-3000. 
Washburn, A.L., Bailey, R.C., 2011. Analyst 136(2), 227-236. 
Whicher, J., Evans, S., 1990. Clin. Chem. 36(7), 1269-1281. 
Wojdasiewicz, P., Poniatowski, Ł.A., Szukiewicz, D., 2014. Mediat. Inflamm. 2014, 1-19. 
Won, J.H., Goldberger, O., Shen-Orr, S.S., Davis, M.M., Olshen, R.A., 2012. Proc. Natl. Acad. Sci. 
109(8), 2848-2853. 
Wu, J., Liu, W., Ge, J., Zhang, H., Wang, P., 2011. Che. Soc. Rev. 40(7), 3483-3495. 
Xu, H., Aguilar, Z.P., Yang, L., Kuang, M., Duan, H., Xiong, Y., Wei, H., Wang, A., 2011. Biomaterials 
32(36), 9758-9765. 
Xue, Q., Lu, Y., Eisele, M.R., Sulistijo, E., Fan, R., Miller-Jensen, K., 2015. Sci. Signal. 8(381), 1-12. 
Yao, G.H., Liang, R.P., Yu, X.D., Huang, C.F., Zhang, L., Qiu, J.D., 2014. Anal. Chem. 87(2), 929-936. 
Yin, Z., Liu, Y., Jiang, L.P., Zhu, J.J., 2011. Biosensm Bioelectronm 26(5), 1890-1894. 
Yuan, L., Hua, X., Wu, Y., Pan, X., Liu, S., 2011. Anal. Chem. 83(17), 6800-6809. 
Yüce, M., Ullah, N., Budak, H., 2015. Analyst 140(16), 5379-5399. 
34 
 
Zhang, B., Liu, B., Tang, D., Niessner, R., Chen, G., Knopp, D., 2012a. Anal. Chem. 84(12), 
5392-5399. 
Zhang, B., Price, J., Hong, G., Tabakman, S.M., Wang, H., Jarrell, J.A., Feng, J., Utz, P.J., Dai, H., 
2013. Nano Res. 6(2), 113-120. 
Zhang, F.T., Nie, J., Zhang, D.W., Chen, J.T., Zhou, Y.L., Zhang, X.X., 2014a. Anal. Chem. 86(19), 
9489-9495. 
Zhang, H., Jiang, B., Xiang, Y., Chai, Y., Yuan, R., 2012b. Analyst 137(4), 1020-1023. 
Zhang, J.J., Cao, J.T., Shi, G.F., Huang, K.J., Liu, Y.M., Ren, S.-W., 2015. Talanta 132, 65-71. 
Zhang, J.J., Liu, Y., Hu, L.H., Jiang, L.P., Zhu, J.J., 2011. Chem. Commun. 47(23), 6551-6553. 
Zhang, K., Ren, T., Wang, K., Zhu, X., Wu, H., Xie, M., 2014b. Chem. Commun. 50(87), 
13342-13345. 
Zhao, W., Schafer, S., Choi, J., Yamanaka, Y.J., Lombardi, M.L., Bose, S., Carlson, A.L., Phillips, J.A., 
Teo, W., Droujinine, I.A., 2011. Nature Nanotech. 6(8), 524-531. 
Zhou, Q., Kwa, T., Liu, Y., Revzin, A., 2012. Expert Rev. Anti Infect. Ther. 10(10), 1079-1081. 
Zhou, W., Gong, X., Xiang, Y., Yuan, R., Chai, Y., 2013. Anal. Chem. 86(1), 953-958. 
Zhu, H., Stybayeva, G., Macal, M., Ramanculov, E., George, M.D., Dandekar, S., Revzin, A., 2008. 
Lab Chip 8(12), 2197-2205. 
